Syndax Pharmaceuticals, Inc. Depreciation
Syndax Pharmaceuticals, Inc. (SNDX) reported Depreciation of $5.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-04
- Syndax Pharmaceuticals, Inc. depreciation for the quarter ending 2026-06-30 was $5.00M.
- Syndax Pharmaceuticals, Inc. depreciation for the quarter ending 2026-03-31 was $4.00M.
- Syndax Pharmaceuticals, Inc. depreciation for the quarter ending 2025-06-30 was $0.00.
- Syndax Pharmaceuticals, Inc. depreciation for the quarter ending 2025-03-31 was $0.00.
- Syndax Pharmaceuticals, Inc. depreciation for fiscal 2025 was $6.00M, a 25.00% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. depreciation for fiscal 2024 was $8.00M, a 33.33% decline from fiscal 2023.
- Syndax Pharmaceuticals, Inc. depreciation for fiscal 2023 was $12.00M, a 63.64% decline from fiscal 2022.
- Syndax Pharmaceuticals, Inc. depreciation for fiscal 2022 was $33.00M, a 23.26% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|
| 2026-06-30 | $5.00M 10-Q · filed 2026-08-04 | $9.00M 10-Q · filed 2026-08-04 | ||
| 2026-03-31 | $4.00M 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $6.00M 10-K · filed 2026-02-26 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-04 | $0.00 10-Q · filed 2026-08-04 | ||
| 2025-03-31 | $0.00 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | $8.00M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $12.00M 10-K · filed 2025-03-03 | |||
| 2022-12-31 | $33.00M 10-K · filed 2024-02-27 | |||
| 2021-12-31 | $43.00M 10-K · filed 2023-02-28 | $43.00K 10-K · filed 2022-03-01 | ||
| 2020-12-31 | $90.00K 10-K · filed 2022-03-01 | |||
| 2019-12-31 | $92.00K 10-K · filed 2020-03-05 | |||
| 2018-12-31 | $78.00K 10-K · filed 2020-03-05 | |||
| 2017-12-31 | $76.00K 10-K · filed 2020-03-05 | |||
| 2016-12-31 | $89.00K 10-K · filed 2019-03-07 | |||
| 2015-12-31 | $21.00K 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $15.00K 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |